Cancer Supportive Care Drugs Market

Cancer Supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects.?

Cancer Supportive Care Drugs Market contains market size and forecasts of Cancer Supportive Care Drugs in Global, including the following market information:

Global Cancer Supportive Care Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Cancer Supportive Care Drugs market was valued at 23800 million in 2021 and is projected to reach US$ 28330 million by 2028, at a CAGR of 2.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Granulocyte-Colony Stimulating Factors (G-CSFS) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cancer Supportive Care Drugs include Amgen, Johnson & Johnson, Novartis, Baxter International, Fagron Group, Teva Pharmaceuticals Industries, F.Hoffmann La-Roche Ltd, Apr Applied Pharma Science Research and Acacia Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Cancer Supportive Care Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cancer Supportive Care Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Cancer Supportive Care Drugs Market Segment Percentages, by Type, 2021 (%)

Granulocyte-Colony Stimulating Factors (G-CSFS)

Erythropoietin-Stimulating Agents (ESAS)

Antiemetics

Bisphosphonates

Opioids

Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)

Others

Global Cancer Supportive Care Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Cancer Supportive Care Drugs Market Segment Percentages, by Application, 2021 (%)

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

Global Cancer Supportive Care Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Cancer Supportive Care Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cancer Supportive Care Drugs revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Cancer Supportive Care Drugs revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Amgen

Johnson & Johnson

Novartis

Baxter International

Fagron Group

Teva Pharmaceuticals Industries

F.Hoffmann La-Roche Ltd

Apr Applied Pharma Science Research

Acacia Pharma

Kyowa Hakko Kirin

Helsinn Healthcare

Heron Pharma

Merck & Co. Inc

Sanofi